



## 5.21.118

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	October 12, 2018
<b>Subject:</b>	Libtayo	<b>Page:</b>	1 of 5

---

**Last Review Date:** June 16, 2022

---

## Libtayo

### Description

#### Libtayo (cemiplimab-rwlc)

#### Background

Libtayo (cemiplimab-rwlc) is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed death receptor-1 (PD-1) and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth (1).

#### Regulatory Status

FDA-approved indication: Libtayo is a programmed death receptor-1 (PD-1) blocking antibody indicated: (1)

- Cutaneous Squamous Cell Carcinoma (CSCC)
  - for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation
- Basal Cell Carcinoma (BCC)
  - for the treatment of patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate
  - for the treatment of patients with metastatic BCC (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate
- Non-Small Cell Lung Cancer (NSCLC)

# 5.21.118

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	October 12, 2018
<b>Subject:</b>	Libtayo	<b>Page:</b>	2 of 5

---

- For the first-line treatment of patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS)  $\geq 50\%$ ] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is:
  - Locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or
  - Metastatic

Libtayo can cause severe and fatal immune-mediated adverse reactions. These can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated dermatologic adverse reactions, and immune-mediated nephritis and renal dysfunction. Patients should be monitored for signs and symptoms of immune-mediated adverse reactions. Evaluate chemical chemistries, including liver and thyroid function, at baseline and periodically during treatment. Libtayo should be withheld or permanently discontinued, and corticosteroids should be administered based on the severity of the reaction (1).

Severe infusion-related reactions may occur during Libtayo treatment. Patients should be monitored for signs and symptoms of infusion-related reactions and the rate of infusion should be interrupted, slowed, or permanently discontinued based on severity of reaction (1).

Libtayo can cause fetal harm when administered to a pregnant woman. The mechanism of action of Libtayo has been shown to lead to increased risk of immune-mediated rejection of a developing fetus resulting in fetal death. Females of reproductive potential should use effective contraception during treatment with Libtayo and for at least 4 months after the last dose (1).

The safety and effectiveness of Libtayo in pediatric patients have not been established (1).

---

## Related policies

Keytruda, Opdivo

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Libtayo may be considered **medically necessary** in patients 18 years of age or older with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), metastatic or locally advanced basal cell carcinoma (BCC), or metastatic or locally advanced non-small cell lung cancer (NSCLC) and if the conditions indicated below are met.

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	October 12, 2018
<b>Subject:</b>	Libtayo	<b>Page:</b>	3 of 5

---

Libtayo may be considered **investigational** in patients less than 18 years of age and for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)
  - a. Patient is not a candidate for curative surgery or curative radiation
2. Metastatic or locally advanced basal cell carcinoma (BCC)
  - a. Patient has previously been treated with a hedgehog pathway inhibitor (e.g., vismodegib) **OR** a hedgehog pathway inhibitor is not appropriate
3. Metastatic or locally advanced non-small cell lung cancer (NSCLC)
  - a. Used as first-line treatment in patients with tumors that have high PD-L1 expression as determined by an FDA-approved test
  - b. **NO** EGFR, ALK, or ROS1 aberrations
  - c. Locally advanced NSCLC **only**: patient is not a candidate for surgical resection or definitive chemoradiation

**AND ALL** of the following:

1. Prescriber agrees to monitor for immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, and nephritis
2. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for at least 4 months after the last dose

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	October 12, 2018
<b>Subject:</b>	Libtayo	<b>Page:</b>	4 of 5

---

1. Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)
2. Metastatic or locally advanced basal cell carcinoma (BCC)
3. Metastatic or locally advanced non-small cell lung cancer (NSCLC)

**AND ALL** of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to monitor for immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, and nephritis
3. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for at least 4 months after the last dose

## Policy Guidelines

### Pre - PA Allowance

None

### Prior - Approval Limits

**Quantity** 4 vials every 84 days

**Duration** 12 months

### Prior – Approval *Renewal* Limits

Same as above

## Rationale

### Summary

Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, metastatic or locally advanced basal cell carcinoma, or metastatic or locally advanced non-small cell lung cancer. Libtayo has warnings for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation (HSCT) and embryo-fetal toxicity. The safety and effectiveness of Libtayo in pediatric patients have not been established (1).

# 5.21.118

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	October 12, 2018
<b>Subject:</b>	Libtayo	<b>Page:</b>	5 of 5

---

Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Libtayo while maintaining optimal therapeutic outcomes.

## References

1. Libtayo [package insert]. Tarrytown, NJ: Regeneron Pharmaceuticals, Inc.; February 2021.
2. NCCN Drugs & Biologics Compendium<sup>®</sup> Cemiplimab-rwlc 2022. National Comprehensive Cancer Network, Inc. Accessed on April 22, 2022.

## Policy History

Date	Action
October 2018	Addition to PA
November 2018	Annual review. Addition of requirement for females of reproductive potential to use contraception during therapy and for at least 4 months after the last dose per SME
June 2019	Annual review and reference update
June 2020	Annual review
March 2021	Addition of indication: basal cell carcinoma (BCC). Addition of indication: non-small cell lung cancer (NSCLC)
June 2021	Annual editorial review and reference update
September 2021	Annual review and reference update
June 2022	Annual review and reference update

## Keywords

**This policy was approved by the FEP<sup>®</sup> Pharmacy and Medical Policy Committee on June 16, 2022 and is effective on July 1, 2022.**